1 Study Coverage 1.1 Hormone Refractory Prostate Cancer (HRPCA) Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million) Introduction 1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Outlook 2017 VS 2022 VS 2028 1.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size for the Year 2017-2028 1.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size for the Year 2017-2028 1.3 Hormone Refractory Prostate Cancer (HRPCA) Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.3.1 The Market Share of United States Hormone Refractory Prostate Cancer (HRPCA) in Global, 2017 VS 2022 VS 2028 1.3.2 The Growth Rate of Hormone Refractory Prostate Cancer (HRPCA) Market Size, United States VS Global, 2017 VS 2022 VS 2028 1.4 Hormone Refractory Prostate Cancer (HRPCA) Market Dynamics 1.4.1 Hormone Refractory Prostate Cancer (HRPCA) Industry Trends 1.4.2 Hormone Refractory Prostate Cancer (HRPCA) Market Drivers 1.4.3 Hormone Refractory Prostate Cancer (HRPCA) Market Challenges 1.4.4 Hormone Refractory Prostate Cancer (HRPCA) Market Restraints 1.5 Study Objectives 1.6 Years Considered 2 Hormone Refractory Prostate Cancer (HRPCA) by Type 2.1 Hormone Refractory Prostate Cancer (HRPCA) Market Segment by Type 2.1.1 Cytotoxic Agents 2.1.2 Anti-Androgens 2.1.3 Vaccines 2.1.4 Radio-Pharmaceuticals 2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017, 2022 & 2028) 2.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2028) 2.4 United States Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017, 2022 & 2028) 2.5 United States Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2028) 3 Hormone Refractory Prostate Cancer (HRPCA) by Application 3.1 Hormone Refractory Prostate Cancer (HRPCA) Market Segment by Application 3.1.1 Hospitals 3.1.2 Ambulatory Surgical Centers 3.1.3 Specialty Clinics 3.1.4 Others 3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017, 2022 & 2028) 3.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2028) 3.4 United States Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017, 2022 & 2028) 3.5 United States Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2028) 4 Global Hormone Refractory Prostate Cancer (HRPCA) Competitor Landscape by Company 4.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Company 4.1.1 Top Global Hormone Refractory Prostate Cancer (HRPCA) Companies Ranked by Revenue (2021) 4.1.2 Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Player (2017-2022) 4.2 Global Hormone Refractory Prostate Cancer (HRPCA) Concentration Ratio (CR) 4.2.1 Hormone Refractory Prostate Cancer (HRPCA) Market Concentration Ratio (CR) (2017-2022) 4.2.2 Global Top 5 and Top 10 Largest Companies of Hormone Refractory Prostate Cancer (HRPCA) in 2021 4.2.3 Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 4.3 Global Hormone Refractory Prostate Cancer (HRPCA) Headquarters, Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million) Type 4.3.1 Global Hormone Refractory Prostate Cancer (HRPCA) Headquarters and Area Served 4.3.2 Global Hormone Refractory Prostate Cancer (HRPCA) Companies Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million) Type 4.3.3 Date of International Companies Enter into Hormone Refractory Prostate Cancer (HRPCA) Market 4.4 Companies Mergers & Acquisitions, Expansion Plans 4.5 United States Hormone Refractory Prostate Cancer (HRPCA) Market Size by Company 4.5.1 Top Hormone Refractory Prostate Cancer (HRPCA) Players in United States, Ranked by Revenue (2021) 4.5.2 United States Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players (2020, 2021 & 2022) 5 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region 5.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region: 2017 VS 2022 VS 2028 5.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2017-2028) 5.2.1 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region: 2017-2022 5.2.2 Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2023-2028) 6 Segment in Region Level & Country Level 6.1 North America 6.1.1 North America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth 2017-2028 6.1.2 North America Hormone Refractory Prostate Cancer (HRPCA) Market Facts & Figures by Country (2017, 2022 & 2028) 6.1.3 U.S. 6.1.4 Canada 6.2 Asia-Pacific 6.2.1 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth 2017-2028 6.2.2 Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Facts & Figures by Region (2017, 2022 & 2028) 6.2.3 China 6.2.4 Japan 6.2.5 South Korea 6.2.6 India 6.2.7 Australia 6.2.8 Taiwan 6.2.9 Indonesia 6.2.10 Thailand 6.2.11 Malaysia 6.2.12 Philippines 6.3 Europe 6.3.1 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth 2017-2028 6.3.2 Europe Hormone Refractory Prostate Cancer (HRPCA) Market Facts & Figures by Country (2017, 2022 & 2028) 6.3.3 Germany 6.3.4 France 6.3.5 U.K. 6.3.6 Italy 6.3.7 Russia 6.4 Latin America 6.4.1 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth 2017-2028 6.4.2 Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Facts & Figures by Country (2017, 2022 & 2028) 6.4.3 Mexico 6.4.4 Brazil 6.4.5 Argentina 6.5 Middle East and Africa 6.5.1 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size YoY Growth 2017-2028 6.5.2 Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Market Facts & Figures by Country (2017, 2022 & 2028) 6.5.3 Turkey 6.5.4 Saudi Arabia 6.5.5 U.A.E 7 Company Profiles 7.1 Astellas Inc 7.1.1 Astellas Inc Company Details 7.1.2 Astellas Inc Business Overview 7.1.3 Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Introduction 7.1.4 Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) 7.1.5 Astellas Inc Recent Development 7.2 Sanofi S.A 7.2.1 Sanofi S.A Company Details 7.2.2 Sanofi S.A Business Overview 7.2.3 Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Introduction 7.2.4 Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) 7.2.5 Sanofi S.A Recent Development 7.3 Dendreon Corporation, Bayer AG 7.3.1 Dendreon Corporation, Bayer AG Company Details 7.3.2 Dendreon Corporation, Bayer AG Business Overview 7.3.3 Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Introduction 7.3.4 Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) 7.3.5 Dendreon Corporation, Bayer AG Recent Development 7.4 Johnson & Johnson 7.4.1 Johnson & Johnson Company Details 7.4.2 Johnson & Johnson Business Overview 7.4.3 Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Introduction 7.4.4 Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) 7.4.5 Johnson & Johnson Recent Development 8 Research Findings and Conclusion 9 Appendix 9.1 Research Methodology 9.1.1 Methodology/Research Approach 9.1.2 Data Source 9.2 Author Details 9.3 Disclaimer

List of Tables Table 1. Hormone Refractory Prostate Cancer (HRPCA) Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028) Table 2. Hormone Refractory Prostate Cancer (HRPCA) Market Trends Table 3. Hormone Refractory Prostate Cancer (HRPCA) Market Drivers Table 4. Hormone Refractory Prostate Cancer (HRPCA) Market Challenges Table 5. Hormone Refractory Prostate Cancer (HRPCA) Market Restraints Table 6. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 7. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million) Table 8. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 9. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million) Table 10. Top Hormone Refractory Prostate Cancer (HRPCA) Companies in Global Market, Ranking by Revenue (2021) Table 11. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue by Player, (US$ Million), 2017-2022 Table 12. Global Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Player, 2017-2022 Table 13. Global Hormone Refractory Prostate Cancer (HRPCA) Companies Market Concentration Ratio (CR5 and HHI) Table 14. Global Hormone Refractory Prostate Cancer (HRPCA) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Hormone Refractory Prostate Cancer (HRPCA) as of 2021) Table 15. Top Players of Hormone Refractory Prostate Cancer (HRPCA) in Global Market, Headquarters and Area Served Table 16. Companies Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million) Type Table 17. Date of International Companies Enter into Hormone Refractory Prostate Cancer (HRPCA) Market Table 18. Companies Mergers & Acquisitions, Expansion Plans Table 19. Top Hormone Refractory Prostate Cancer (HRPCA) Players in United States Market, Ranking by Revenue (2021) Table 20. United States Hormone Refractory Prostate Cancer (HRPCA) Revenue by Players, (US$ Million), 2020, 2021 & 2022 Table 21. United States Hormone Refractory Prostate Cancer (HRPCA) Revenue Share by Players, 2020, 2021 & 2022 Table 22. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (US$ Million): 2017 VS 2022 VS 2028 Table 23. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Region (2017-2022) & (US$ Million) Table 24. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size Forecast by Region (2023-2028) & (US$ Million) Table 25. North America Hormone Refractory Prostate Cancer (HRPCA) Sales in Value by Country (2017-2028) & (US$ Million) Table 26. Asia Pacific Hormone Refractory Prostate Cancer (HRPCA) Sales in Value by Region (2017-2028) & (US$ Million) Table 27. Europe Hormone Refractory Prostate Cancer (HRPCA) Sales in Value by Country (2017-2028) & (US$ Million) Table 28. Latin Americaa Hormone Refractory Prostate Cancer (HRPCA) Sales in Value by Country (2017-2028) & (US$ Million) Table 29. Middle East and Africa Hormone Refractory Prostate Cancer (HRPCA) Sales in Value by Country (2017-2028) & (US$ Million) Table 30. Astellas Inc Company Details Table 31. Astellas Inc Business Overview Table 32. Astellas Inc Hormone Refractory Prostate Cancer (HRPCA) Product Table 33. Astellas Inc Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million) Table 34. Astellas Inc Recent Development Table 35. Sanofi S.A Company Details Table 36. Sanofi S.A Business Overview Table 37. Sanofi S.A Hormone Refractory Prostate Cancer (HRPCA) Product Table 38. Sanofi S.A Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million) Table 39. Sanofi S.A Recent Development Table 40. Dendreon Corporation, Bayer AG Company Details Table 41. Dendreon Corporation, Bayer AG Business Overview Table 42. Dendreon Corporation, Bayer AG Hormone Refractory Prostate Cancer (HRPCA) Product Table 43. Dendreon Corporation, Bayer AG Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million) Table 44. Dendreon Corporation, Bayer AG Recent Development Table 45. Johnson & Johnson Company Details Table 46. Johnson & Johnson Business Overview Table 47. Johnson & Johnson Hormone Refractory Prostate Cancer (HRPCA) Product Table 48. Johnson & Johnson Revenue in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) & (US$ Million) Table 49. Johnson & Johnson Recent Development Table 50. Research Programs/Design for This Report Table 51. Key Data Information from Secondary Sources Table 52. Key Data Information from Primary Sources List of Figures Figure 1. Hormone Refractory Prostate Cancer (HRPCA) Product Picture Figure 2. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 3. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size 2017-2028 (US$ Million) Figure 4. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size, (US$ Million), 2017 VS 2022 VS 2028 Figure 5. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size 2017-2028 (US$ Million) Figure 6. United States Hormone Refractory Prostate Cancer (HRPCA) Market Share in Global 2017-2028 Figure 7. Hormone Refractory Prostate Cancer (HRPCA) Report Years Considered Figure 8. Product Picture of Cytotoxic Agents Figure 9. Product Picture of Anti-Androgens Figure 10. Product Picture of Vaccines Figure 11. Product Picture of Radio-Pharmaceuticals Figure 12. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type in 2022 & 2028 Figure 13. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2028) & (US$ Million) Figure 14. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2017-2028) Figure 15. United States Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type in 2022 & 2028 Figure 16. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size by Type (2017-2028) & (US$ Million) Figure 17. United States Hormone Refractory Prostate Cancer (HRPCA) Market Share by Type (2017-2028) Figure 18. Product Picture of Hospitals Figure 19. Product Picture of Ambulatory Surgical Centers Figure 20. Product Picture of Specialty Clinics Figure 21. Product Picture of Others Figure 22. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application in 2022 & 2028 Figure 23. Global Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2028) & (US$ Million) Figure 24. Global Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2017-2028) Figure 25. United States Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application in 2022 & 2028 Figure 26. United States Hormone Refractory Prostate Cancer (HRPCA) Market Size by Application (2017-2028) & (US$ Million) Figure 27. United States Hormone Refractory Prostate Cancer (HRPCA) Market Share by Application (2017-2028) Figure 28. North America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate 2017-2028 (US$ Million) Figure 29. U.S. Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 30. Canada Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 31. Europe Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate 2017-2028 (US$ Million) Figure 32. Germany Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 33. France Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 34. U.K. Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 35. Italy Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 36. Russia Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 37. Asia-Pacific Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate 2017-2028 (US$ Million) Figure 38. China Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 39. Japan Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 40. South Korea Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 41. India Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 42. Australia Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 43. Taiwan Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 44. Indonesia Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 45. Thailand Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 46. Malaysia Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 47. Philippines Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 48. Latin America Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate 2017-2028 (US$ Million) Figure 49. Mexico Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 50. Brazil Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 51. Argentina Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 52. Middle East & Africa Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate 2017-2028 (US$ Million) Figure 53. Turkey Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 54. Saudi Arabia Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 55. U.A.E Hormone Refractory Prostate Cancer (HRPCA) Market Size Growth Rate (2017-2028) & (US$ Million) Figure 56. Astellas Inc Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) Figure 57. Sanofi S.A Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) Figure 58. Dendreon Corporation, Bayer AG Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) Figure 59. Johnson & Johnson Revenue Growth Rate in Hormone Refractory Prostate Cancer (HRPCA) Business (2017-2022) Figure 60. Bottom-up and Top-down Approaches for This Report Figure 61. Data Triangulation Figure 62. Key Executives Interviewed

Astellas Inc Sanofi S.A Dendreon Corporation, Bayer AG Johnson & Johnson